SG174043A1 - A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production - Google Patents

A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production Download PDF

Info

Publication number
SG174043A1
SG174043A1 SG2011056447A SG2011056447A SG174043A1 SG 174043 A1 SG174043 A1 SG 174043A1 SG 2011056447 A SG2011056447 A SG 2011056447A SG 2011056447 A SG2011056447 A SG 2011056447A SG 174043 A1 SG174043 A1 SG 174043A1
Authority
SG
Singapore
Prior art keywords
compound
fluoro
trifluoropentanamide
reaction
added
Prior art date
Application number
SG2011056447A
Other languages
English (en)
Inventor
Jr John E Starrett
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG174043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG174043A1 publication Critical patent/SG174043A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG2011056447A 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production SG174043A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31

Publications (1)

Publication Number Publication Date
SG174043A1 true SG174043A1 (en) 2011-09-29

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011056447A SG174043A1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
SG2011056454A SG174044A1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011056454A SG174044A1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Country Status (28)

Country Link
US (2) US8084477B2 (OSRAM)
EP (3) EP2295417B1 (OSRAM)
JP (1) JP5460605B2 (OSRAM)
KR (1) KR20100075575A (OSRAM)
CN (2) CN101910141B (OSRAM)
AR (1) AR069135A1 (OSRAM)
AT (1) ATE502022T1 (OSRAM)
AU (1) AU2008319122A1 (OSRAM)
BR (1) BRPI0818837A2 (OSRAM)
CA (1) CA2704360A1 (OSRAM)
CL (1) CL2008003271A1 (OSRAM)
CO (1) CO6270332A2 (OSRAM)
CY (2) CY1112337T1 (OSRAM)
DE (1) DE602008005636D1 (OSRAM)
DK (2) DK2205575T3 (OSRAM)
EA (2) EA201171439A1 (OSRAM)
ES (2) ES2390042T3 (OSRAM)
HR (2) HRP20110219T1 (OSRAM)
IL (1) IL205406A0 (OSRAM)
MX (1) MX2010004319A (OSRAM)
NZ (1) NZ584545A (OSRAM)
PE (1) PE20091394A1 (OSRAM)
PL (2) PL2295417T3 (OSRAM)
PT (2) PT2295417E (OSRAM)
SG (2) SG174043A1 (OSRAM)
SI (2) SI2205575T1 (OSRAM)
TW (1) TW200927099A (OSRAM)
WO (1) WO2009058552A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162498A0 (en) 2001-12-20 2005-11-20 Bristol Myers Squibb Co (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
AU2009342632A1 (en) * 2009-03-19 2011-09-01 Bristol-Myers Squibb Company A novel alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
EP2719688B1 (en) * 2010-03-12 2016-07-20 Nippon Soda Co., Ltd. Process for producing tetrazolyloxime derivatives
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
JP2013542973A (ja) * 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
KR20190098998A (ko) 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
CA3144324A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
CN1238688A (zh) 1996-07-22 1999-12-15 孟山都公司 硫羟磺酰胺金属蛋白酶抑制剂
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
IL144347A0 (en) 1999-01-27 2002-05-23 American Cyanamid Co Acetylenic sulfonamide thiol tace inhibitors
WO2000050391A1 (en) 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
JP4563681B2 (ja) * 2001-12-14 2010-10-13 レイセオン カンパニー 正確に整列されたレンズ構造およびその製造方法
IL162498A0 (en) * 2001-12-20 2005-11-20 Bristol Myers Squibb Co (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same
NZ535591A (en) * 2002-02-28 2006-07-28 Astrazeneca Ab Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
ATE362368T1 (de) * 2003-03-20 2007-06-15 Santhera Pharmaceuticals Ch Substituierte piperidin- und piperazin-derivative als melanocortin-4 receptor modulatoren
CL2004000647A1 (es) * 2003-03-31 2005-02-04 Wyeth Corp Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
US7144894B2 (en) * 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
TW200736195A (en) * 2006-02-17 2007-10-01 Wyeth Corp Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
PL2205575T3 (pl) 2011-09-30
HK1141801A1 (en) 2010-11-19
WO2009058552A1 (en) 2009-05-07
BRPI0818837A2 (pt) 2015-04-22
ES2390042T3 (es) 2012-11-06
HK1155161A1 (en) 2012-05-11
CN101910141B (zh) 2012-12-19
EP2205575A1 (en) 2010-07-14
CO6270332A2 (es) 2011-04-20
CY1113346T1 (el) 2016-06-22
US20120088925A1 (en) 2012-04-12
JP2011502153A (ja) 2011-01-20
PT2295417E (pt) 2012-09-26
CY1112337T1 (el) 2015-12-09
US8350084B2 (en) 2013-01-08
AU2008319122A1 (en) 2009-05-07
JP5460605B2 (ja) 2014-04-02
DK2205575T3 (da) 2011-07-11
EP2295417B1 (en) 2012-07-04
TW200927099A (en) 2009-07-01
EA201171439A1 (ru) 2012-05-30
DE602008005636D1 (de) 2011-04-28
CN101910141A (zh) 2010-12-08
SG174044A1 (en) 2011-09-29
PL2295417T3 (pl) 2012-11-30
CL2008003271A1 (es) 2009-07-10
PE20091394A1 (es) 2009-09-25
US8084477B2 (en) 2011-12-27
IL205406A0 (en) 2010-12-30
EA201000714A1 (ru) 2010-10-29
EP2471769A1 (en) 2012-07-04
PT2205575E (pt) 2011-05-23
EA016447B1 (ru) 2012-05-30
ES2361283T3 (es) 2011-06-15
MX2010004319A (es) 2010-04-30
HRP20110219T1 (hr) 2011-04-30
EP2295417A1 (en) 2011-03-16
EP2205575B1 (en) 2011-03-16
SI2205575T1 (sl) 2011-07-29
ATE502022T1 (de) 2011-04-15
KR20100075575A (ko) 2010-07-02
CA2704360A1 (en) 2009-05-07
AR069135A1 (es) 2009-12-30
SI2295417T1 (sl) 2012-11-30
NZ584545A (en) 2011-04-29
HRP20120703T1 (hr) 2012-09-30
US20090111858A1 (en) 2009-04-30
DK2295417T3 (da) 2012-10-15
CN102718689A (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
EP2205575B1 (en) A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
JP2011523412A (ja) スフィンゴシンリン酸受容体の新規なモジュレーター
EP2408450B1 (en) Alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
EP2408757B1 (en) A novel alpha-(n-sulfonamido) acetamide compound incorporating deuterium as inhibitor of beta amyloid peptide production
US20110071199A1 (en) Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US8093276B2 (en) Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
HK1141801B (en) A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production